<DOC>
	<DOCNO>NCT00222144</DOCNO>
	<brief_summary>The primary goal study determine effect combination Gleevec Taxotere lung cancer term control reduction cancer size . The study also test lung cancer see presence certain protein call receptor platelet derive growth factor influence effect treatment .</brief_summary>
	<brief_title>Study Gleevec Taxotere Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The purpose study evaluate response rate Gleevec Taxotere patient recurrent non-small cell lung cancer . Also determine expression PDGF-R , phosphorylated PDGF-r C-kit original tissue correlate response . If patient tumor accessible location , ask consent patient obtain biopsy therapy ass molecular marker .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>One prior chemotherapy treatment : use single chemotherapy regimen contain one drug . Regimen must platinum agent ( cisplatin carboplatin ) . Prior biological treatment wo n't count chemotherapy treatment . Chemoradiation prior induction adjuvant chemotherapy +/ chemoradiation constitute one prior chemotherapy regimen . Patients may receive Docetaxel . Taxol part initial therapy allow . Documented recurrent/progressive disease radiographic exam ( CT scan , MRI , bone scan CXR ) , clinical exam ( presence palpable node ) biopsy . No sign clinically active brain metastasis spinal cord compression . If patient brain metastasis cord compression , patient eligible stable without deterioration performance status radiation therapy corticosteroid . Cases pleural effusion must another site disease measurement followup . ECOG performance status 01 Bidimensional measurable disease ( ≥ 1 cm CT radiogram ; physical exam alone permissible radiographically measurable tumor ) Laboratory : ANC ≥ 1,500/mm3 , Hemoglobin &gt; 8g/dl , platelet ≥ 100,000/mm3 , Total Bilirubin ≤ 1.5 mg/dl , Creatinine ≤ 2.0 mg/dl , Transaminase ( AST/ALT ) ≤ 2.5 X upper normal limit ALK phosphatase ≤ Upper normal limit OR ALK may 4X ULN transaminase ≤ ULN . Age ≥ 18 year old Histologic cytologic diagnosis NSCLC , biopsy diagnosis recurrence . Histology may include large cell , squamous cell , undifferentiated , bronchioalveolar adenocarcinoma small cell lung cancer mix small nonsmall cell lung cancer , carcinoid . Mixed histology nonsmall cell lung cancer allow , i.e . : large cell neuroendocrine carcinoma . IHC biopsy specimen , available , PDGFR . Insufficient tissue preclude study enrollment . FEV1 &gt; 800 cc ECOG performance status 2 bad Psychological , familial , sociological geographical condition , prevent weekly medical followup compliance study protocol Radiation 30 % bone marrow More 1 different prior cytotoxic chemotherapy regimen CoMorbid condition would affect survival : grade III/IV cardiac problem define New York Heart Association ( e.g . endstage congestive heart failure , myocardial infarction within 6 month study ) , random uncontrolled blood sugar ≥300 mg/dl , unstable angina , active infection antibiotic , FEV1 le 800 cc , patient know chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) Use investigational agent chemotherapy within 4 week Pregnant nursing woman woman men reproductive potential unless use effective contraception throughout study 3 month discontinuation study drug . No active invasive cancer . Patient &lt; 5 year free another malignancy except : primary malignancy n't currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Patients history hypersensitivity taxane , Polysorbate 80 gemcitabine could tolerate treatment even 24 H premedication Decadron Benadryl . ( If patient prior hypersensitivity , receive 24 H premedication taxane , patient may eligible he/she tolerate one cycle 24 H premedication ) . Existing peripheral neuropathy CTC Version 3 &gt; grade 2 Patient know diagnosis human immunodeficiency virus ( HIV ) infection Patients take oral medication . Percutaneous gastrostomy feed tube allow Gleevec give PEG Patient major surgery within 2 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>